R Ohno
About
In The Last Decade
R Ohno
34 papers receiving 422 citations
Peers
Comparison fields: 5 of 62
- Hematology 225
- Oncology 151
- Molecular Biology 106
- Immunology 80
- Public Health, Environmental and Occupational Health 77
Countries citing papers authored by R Ohno
This map shows the geographic impact of R Ohno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Ohno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Ohno more than expected).
Fields of papers citing papers by R Ohno
This network shows the impact of papers produced by R Ohno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Ohno. The network helps show where R Ohno may publish in the future.
Co-authorship network of co-authors of R Ohno
This figure shows the co-authorship network connecting the top 25 collaborators of R Ohno. A scholar is included among the top collaborators of R Ohno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Ohno. R Ohno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group]. | 2 |
| 3 | [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma]. | 5 |
| 4 | [Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia]. | 1 |
| 5 | 1 | |
| 6 | [Two cases of encephalo-myelo-radiculoneuropathy, triggered by herpes simplex virus type-1 infection]. | 1 |
| 7 | 48 | |
| 8 | 1 | |
| 9 | 5 | |
| 10 | 27 | |
| 11 | Establishment and characterization of a new human Bence Jones-type myeloma cell line, NOP-2. | 11 |
| 12 | 7 | |
| 13 | 2 | |
| 14 | 1 | |
| 15 | 8 | |
| 16 | [Clinical studies on interferon in cancer therapy in Japan]. | 2 |
| 17 | [Early phase II trial of bestrabucil in hematological malignancies]. | 1 |
| 18 | Adoptive immunotherapy against a local or widespread tumor of a highly malignant and poorly immunogenic mouse leukemia L1210. | 1 |
| 19 | 6 | |
| 20 | L-asparaginase: suppression of the immune response of mice to sheep red blood cells. | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.